It Seems Conatus Pharmaceuticals Inc. (CNAT) Will Go Down. Just Reaches Yearly Low

April 16, 2018 - By Maria Brooks

Investors sentiment decreased to 1.1 in 2017 Q4. Its down 0.73, from 1.83 in 2017Q3. It fall, as 14 investors sold Conatus Pharmaceuticals Inc. shares while 17 reduced holdings. 11 funds opened positions while 23 raised stakes. 11.71 million shares or 7.58% more from 10.89 million shares in 2017Q3 were reported.
State Of Wisconsin Investment Board has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Aqr Capital Management Ltd Com holds 0% or 734,261 shares. Alliancebernstein Lp holds 10,800 shares. Millennium Limited Co invested in 0% or 378,005 shares. Denver Advsr Lc stated it has 10,715 shares or 0% of all its holdings. Northern has invested 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Macquarie Ltd accumulated 130,300 shares. Gp One Trading Lp stated it has 0% of its portfolio in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT). Comml Bank Of Ny Mellon Corporation holds 0% in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) or 215,843 shares. Fny Managed Accounts Limited Com holds 0% or 800 shares. Balyasny Asset Mngmt Llc holds 0% or 29,727 shares in its portfolio. Tiaa Cref Investment Management Limited Co accumulated 216,766 shares. Mpm Asset Mgmt Ltd invested in 2.10M shares. Strs Ohio has 26,700 shares for 0% of their portfolio. Manufacturers Life Ins Company The has 6,511 shares.

The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) hit a new 52-week low and has $3.50 target or 4.00 % below today’s $3.65 share price. The 8 months bearish chart indicates high risk for the $109.72M company. The 1-year low was reported on Apr, 16 by Barchart.com. If the $3.50 price target is reached, the company will be worth $4.39M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.19% or $0.2 during the last trading session, reaching $3.65. About 404,025 shares traded. Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has risen 12.92% since April 16, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on May, 3. They expect $-0.17 earnings per share, down 21.43 % or $0.03 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 13.33 % negative EPS growth.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Ratings Coverage

Among 4 analysts covering Conatus Pharmaceuticals (NASDAQ:CNAT), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conatus Pharmaceuticals had 6 analyst reports since February 8, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, March 1 by Oppenheimer. H.C. Wainwright maintained the stock with “Buy” rating in Thursday, April 5 report. The rating was maintained by Oppenheimer with “Buy” on Thursday, March 22. The firm has “Buy” rating given on Wednesday, March 7 by Oppenheimer.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $109.72 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.